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Efficacy of oral azithromycin versus topical tetra-
cycline in mass treatment of endemic trachoma
Nicole Fraser-Hurt,1 Robin L. Bailey,2 Simon Cousens,3 Denise Mabey,4 Hannah Faal,5 & David C.W. Mabey6
Objective To compare the impact of mass treatment with oral azithromycin and topical tetracycline on the
prevalence of active trachoma.
Methods A total of 1803 inhabitants from 106 households of eight Gambian villages were randomized, in pairs,
to receive either three doses of azithromycin at weekly intervals, or daily topical tetracycline over 6 weeks. Ocular
examinations were conducted before treatment, and 2, 6 and 12 months after treatment.
Findings Prior to treatment, 16% of the study participants had active trachoma. Two months after treatment, the
prevalence of trachoma was 4.6% and 5.1% in the azithromycin and the tetracycline groups, respectively (adjusted
odds ratio (OR) = 1.09; 95% confidence interval (CI) = 0.53, 2.02). Subsequently, the prevalence rose to 16% in
the tetracycline group, while remaining at 7.7% in the azithromycin group (adjusted OR at 12 months = 0.52; 95%
CI = 0.34, 0.80). At 12 months post-treatment, there were fewer new prevalent cases in the azithromycin group,
and trachoma resolution was significantly better for this group (adjusted OR = 2.02; 95% CI = 1.42, 3.50).
Conclusion Oral azithromycin therefore appears to offer a means for controlling blinding trachoma. It is easy to
administer and higher coverages may be possible than have been achieved hitherto.
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Comparative study; Gambia (source: MeSH ).
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Introduction
Trachoma is caused by the recurrent, chronic
infection of the eye with Chlamydia trachomatis
serotypes A, B, Ba or C, and progresses from
inflammation to conjunctival scarring, lid deformi-
ties, corneal abrasion and visual impairment. It is the
most common infectious cause of blindness, and is
responsible for an estimated 15% of global blindness
(1). Active trachoma affects an estimated 150 million
people (2), and about 5.5 million are blind as a
consequence of the disease. Blinding trachoma
mainly occurs in rural, resource-poor areas of Africa
and Asia (for a review of risk factors see Mabey et al.
(3)). The importance of within-household transmis-
sion is supported by epidemiological observations
(4, 5) and by serotyping and genotyping results (6–8).
International efforts to control the disease are
based on the SAFE strategywhich combines Surgery,
Antibiotics, Facial cleanliness and Environmental
improvement. The Global Elimination of Trachoma
as a disease of public health importance by 2020
(GET 2020) is currently the overall goal in trachoma
control efforts (9). Active trachoma is routinely
treated with tetracycline eye ointment applied daily
for 6 weeks. However, topical treatment is not
practical for mass treatment since the ointment is
difficult and uncomfortable to apply, it blurs the
vision, and it must be performed daily over an
extended period of time.
Systemic antibiotics tested in randomized
controlled trials have shown some efficacy against
active trachoma but carried a high risk of adverse
side-effects. Treatment with sulfonamides (trisulfa-
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pyrimidine (10) and sulfamethoxypyridazine (11)
given over 3 weeks, and sulfadimethoxine (12)
administered over 5 months), which were evaluated
in the 1960s, all have the major drawback of causing
systemic complications. The subsequently tested oral
tetracyclines, doxycycline (13, 14) and minocycline
(15), administered for periods up to 1 year, may cause
adverse effects in children and fetuses. Under field
conditions the cost of delivery of intensive, super-
vised topical or multidose oral therapy to rural
populations is prohibitive.
Systemic azithromycin is highly effective as a
single-dose therapy for genitalC. trachomatis infection
(9, 16), and appears to offer a novel alternative for
trachoma control. It has a half-life in tissue of 2–
3 days (17) and a good safety profile in all age groups.
A trial in the Gambia established that a single dose of
azithromycin (20 mg/kg) was as effective as six
weeks of twice-daily topical tetracycline (18); but
reinfection is commonwhen only individual cases are
treated, and 40% of subjects were reinfected
6 months after treatment. In a study on dosage
schedules involving Egyptian children with active
trachoma, Dawson et al. (19) found that the
prevalence of both severe trachoma andC. trachomatis
infection was similar after 1–6 doses of oral
azithromycin or 30 days of topical tetracycline.
Tabbara et al. (20) reported comparable efficacy with
only a single dose of azithromycin.
There is some experience in mass or selective
mass treatment using topical and oral compounds.
Vertical control programmes in Saudi Arabia in the
1960s and late 1980s and in Tunisia in the 1980s
combined topical mass treatment with hygiene
promotion and eyelid surgery (9). Recent interven-
tion studies in the United Republic of Tanzania
assessed topical mass treatment and face washing
(21). Tetracycline regimens have been shown to be
effective primarily in highly exposed schoolchildren
(13). Resnikoff et al. (22) tested oral minocycline in
selective mass treatment. Mass treatment has gen-
erally, in the absence of improvements in living
standards, been accompanied by substantial treat-
ment failures and a short-lived treatment response.
The latest recommendation from WHO is that all
children should be treated in communities where
more than 20% of children show signs of active
trachoma. However, in hyperendemic areas the main
group responsible for transmission is pre-school
children, who are not easily reached through the
existing channels.
The ACT (Azithromycin in Control of Tra-
choma) study was conducted with the objective of
comparing the efficacy of mass treatment with oral
azithromycin and topical tetracycline in the United
Republic of Tanzania, Egypt, and the Gambia. The
microbiological findings of the ACT study have been
presented in detail by Schachter et al. (23). The
present article presents the clinical and selected
microbiological results of the ACT trial conducted in
the Gambia.
Study design and methods
Study area and participants
The intervention area consisted of eight trachoma-
endemic villages in the Sanjal Region of the Upper
Baddibu District, located within 10 km of each other
and approximately 20 km east of Farafenni town on
the north bank of the River Gambia. The main local
ethnic groups are Wolof, Fula and Mandinka (24).
Most of the population live from subsistence farm-
ing, with an average annual per capita income of
around US$ 200. The villages are composed of
compounds inhabited by the members of one
extended family and their livestock (‘‘households’’).
Water is obtained from deep wells. All residents who
were present at the pre-treatment survey were eligible
for participation in the trial. The villages were
matched in pairs of similar size, and azithromycin
and tetracycline were allocated randomly within these
pairs.
Diagnosis and case definition
The clinical assessments were performed in the field
using a Heine 62.4 binocular loupe and handheld
lights. Diagnosis of trachoma and its sequelae were
based on the WHO grading scheme (25, 26). Active
trachoma was defined as the presence of either
follicular disease (TF) or intense disease (TI). Two
experienced tropical ophthalmologists performed all
the examinations after careful standardization.
Treatment
In the four villages allocated to azithromycin, women
of childbearing age received erythromycin (500 mg)
twice daily for 14 days, or amoxycillin (500 mg) three
times daily for 14 days in cases of intolerance. All
other residents received azithromycin (20 mg/kg to a
maximum of 1g) on days 1, 8 and 15. In the
tetracycline villages, the entire population received a
supervised application of 1% tetracycline ointment to
both eyes daily for 6 weeks. Compliance was
determined by trained volunteers who recorded the
ingestion of tablets or application of ointment.
Follow-up
Three cross-sectional ophthalmic surveys were
performed 2, 6 and 12 months after treatment.
Census updates were completed at least once per
month. Village residents who had not been present
at the pre-treatment examination (and therefore did
not belong to the intention-to-treat cohort) but
moved back to their village of residence during
follow-up were also examined during the follow-up
period, but were not included in the intention-to-
treat analysis. Subjects with active disease were
treated at the end of the trial with oral azithromycin
or topical tetracycline. All subjects needing surgery
were referred to the local health centre, where
resources were provided to enable the operations to
be conducted free of charge.
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Ethical approval
The trial was approved by the joint Medical Research
Council/Gambia Government Ethics Committee
and the Ethical Committee of the London School of
Hygiene and Tropical Medicine. Meetings were held
in each village where the aims and methods of the
study were explained, and community consent was
obtained at this time. Individual verbal informed
consent was obtained before clinical examination,
after the methods were explained in the appropriate
local language.
Statistical methods
Data were entered through a customized system
using Paradox 3.5 software, with automatic check
and validation features, together with manual checks
by a supervisor. Analyses were performed with Stata
version 5.0 (http://www.stata.com), based on the
intention-to-treat cohort formed by the individuals
assessed in the pre-treatment survey. The primary
endpoint for the efficacy assessment was active
trachoma, i.e. TF or TI. Clinical cure was defined as
the resolution of active trachoma, i.e. absence of TF
and TI. Outcomes examined for the assessment of
treatment efficacywere the point prevalence of active
trachoma at 2, 6 and 12 months post-treatment, the
occurrence of new prevalent cases at 12 months or
any time post-treatment, and disease resolution at 2, 6
or 12 months post-treatment.
The w2 test was used to investigate individual-
level factors associated with attendance at follow-up
surveys. Point estimates of the odds ratio for the
comparison of azithromycin with tetracycline, ad-
justed for age, latrine ownership and, where appro-
priate, trachoma status at baseline, were obtained
using logistic regression with individual records.
Confidence intervals around these point estimates
were obtained by the bootstrap method (27). To take
account of the cluster randomization, re-sampling of
clusters rather than individuals was performed. For
each analysis 1000 bootstrap samples were drawn and
95% confidence intervals (CI) ascertained using the
percentile method.
Results
Pre-treatment survey
Participants and group allocations. A total of
1803 individuals were examined in the eight inter-
vention villages between 4 July and 4 October 1994
(Table 1). Of the azithromycin villages, two were
inhabited exclusively by members of the Wolof
ethnic group, one bymembers of the Fula group, and
one by both ethnic groups. Three tetracycline villages
were inhabited exclusively by Wolofs, while the
fourth also had a small number of Fulani.
The proportions of males in the azithromycin
and tetracycline groups were 56% and 59%,
respectively. The mean ages in the two groups were
21.4 years and 20.7 years, respectively, and were
similar within pairs, as were the proportions of the
population aged less than 10 years (Table 1). The
mean numbers of individuals per household were
17.2 and 15.9 in the azithromycin and tetracycline
groups, respectively. Households with, on average,
more than two individuals per bedroom were more
common in the azithromycin villages (65%) than in
the tetracycline villages (53%). The presence of
latrines was reported in 25% and 32% of households
in azithromycin and tetracycline villages, respectively.
Overall, 34% of children up to 10 years of age were
observed to have ocular flies present at the time of
the baseline examination.
Ocular examination results. TF (26) was
diagnosed in 9.4% of individuals allocated to
azithromycin and in 14.6% of individuals allocated
to tetracycline. The prevalence of TI was 7.4% in the
azithromycin group and 7.1% in the tetracycline
group. The age distribution of trachoma markers
showed the typical pattern for an endemic area, with
inflammation in children of pre-school age, and
scarring, potentially disabling and disabling lesions in
adolescents and adults (Fig. 1). Overall, 16% of all
participants had active trachoma (TF or TI) at
baseline (Table 1), with similar prevalences in males
(15%) and females (18%). The disease prevalence in
the azithromycin group was 14.4%, compared with
18.4% in the tetracycline group (Table 2). The
greatest difference in prevalence was observed in the
5–9 year-old age group.
Classification of villages. The prevalence of
active disease among children up to 10 years of age
(assessed in at least 50 individuals) is a key criterion in
the choice of control strategy (9). Apart from one
village (Sinchu Pallen) with a 17% prevalence of
active disease in children, all other villages would be
eligible for mass treatment in the current framework
of trachoma control strategies based on their disease
prevalence exceeding 20% in the indicator group
(Table 1).
Treatment and compliance. The median inter-
vals between baseline examination and treatment were
1.2 months and 0.9 months for the azithromycin and
tetracycline groups, respectively. Compliance with
treatment was defined as at least one dose of
azithromycin (or one week of erythromycin), or at
least 4 weeks of tetracycline application. Data on
compliance were available for 96% of the 1803 parti-
cipants. A total of 228 individuals received erythro-
mycin instead of azithromycin. The overall treatment
compliance was 97%, and was slightly higher in the
azithromycin-treated (range, 94–100%) than in the
tetracycline-treated villages (range, 89–98%).
Post-treatment surveys
Schedule of surveys and attendance. The three post-
treatment surveys were conducted after median
periods (post-treatment) of 2.7, 6.1 and 11.9 months
(azithromycin group) and 2.8, 6.4 and 12.2 months
(tetracycline group). These follow-up surveys were
attended by 747 (79%), 487 (51%), and 573 (61%) of
the individuals randomized to azithromycin, and by
677 (79%), 383 (45%), and 427 (50%) of those
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randomized to tetracycline. One azithromycin vil-
lage, Balo, had very poor post-treatment follow-up,
51% at 2 months, 5% at 6 months, and 0% at
12 months. Individual factors statistically associated
with attendance at none or only one of the three post-
treatment surveys were increasing age (P = 0.02),
Wolof ethnicity (P <0.001), absence of active
trachoma at baseline (P = 0.001), and non-compli-
ance with treatment (P = 0.06).
Effect of treatment on active disease in
individuals. Table 2 presents the age- and sex-
specific prevalences of active disease, by treatment
group, at 6 and 12 months post-treatment. Fig. 2
shows the prevalence of follicular and intense disease
in the two intervention groups at 2, 6 and 12 months
post-treatment. Table 3 presents estimates of the
effect on active trachoma of using azithromycin
rather than tetracycline at 6 and 12 months post-
treatment. Fig. 3 shows the evolution of village
prevalences of active disease over time.
At 2 months post-treatment there was little
indication of any difference in active trachoma
prevalence between the two groups (Table 3). By
12 months post-treatment, however, there was evi-
dence that the overall prevalence of active disease was
lower in the azithromycin group (adjusted odds ratio
(OR) = 0.52; 95% CI = 0.34, 0.80). Similar patterns
were observed when separate analyses were per-
formed for those with and without active disease at
baseline. At 12 months post-treatment, among
individuals without active trachoma at baseline, a
smaller number in the azithromycin group than in the
tetracycline group had become prevalent cases
(adjusted OR = 0.54); however, the 95% CI around
this estimate is wide (0.22, 1.15). Among individuals
with active disease at baseline, a higher proportion
among those receiving azithromycin had resolved at
12months (adjustedOR= 2.02; 95%CI= 1.42, 3.50).
The relationship between presence of active
disease and C. trachomatis infection was determined
among the participants for whom both clinical and
microbiological data were available. In the follow-up
survey at one year, there was a strong association
between infection and disease in both treatment
groups (azithromycin group: w2 test = 11.1, P =
0.001; tetracycline group: w2 test = 22.3, P <0.001).
Participants with active trachoma at baseline were
significantly more likely to have infection one year
after treatment in the tetracycline group (w2 test =
9.6, P = 0.002), but not in the azithromycin group
(w2 test = 1.24, P = 0.27). Among all those with
disease at baseline, the prevalence of infection at one
year was 21.4% in the tetracycline group (n = 103)
and 11.7% in the azithromycin group (n = 77).
The reduction in the prevalence of active
trachoma at 12 months post-treatment among those
receiving azithromycin appears to hold for both sexes
and for children up to 14 years of age (Table 2). There
is less indication of a difference between the two
treatment groups for adults. Interestingly, there was a
considerable reduction in the prevalence of TI as
compared to TF in both intervention groups (Fig. 2).
Prior to treatment, approximately 7% of the
participants were positive for TI. After 1 year,
8 (1.4%) of those allocated to azithromycin and
12 (2.8%) of those allocated to tetracycline had TI.
In two of the three azithromycin villages with
follow-up at 12 months (Ndowen and Lumen), the
prevalence of active disease remained substantially
lower than it had been at baseline (Fig. 3). In the third
village it remained slightly lower. Among the four
tetracycline villages, prevalence at 12 months post-
treatment was only substantially lower than at baseline
in one village (Sambo Sotor). In two other villages
(Checken and Keur Bamba Lowe) the prevalences at
12 months were similar to those at baseline, while in
the remaining village (Njaien) the prevalence was
substantially higher at 12 months post-treatment.
Discussion
The present trial of community randomized mass
treatment with azithromycin complements the experi-
Table 1. Baseline characteristics of the eight study villages for treatment with azithromycin (AZ) or
tetracycline (TC)
Pair Treatment Village No. of No. of Mean age No. (%) of % Prevalence of active
allocation households individuals (years) households trachoma among
with a latrine
All ages 0–9-year-
olds
1 AZ Ndowen 6 158 18.3 4 (67) 20 39
TC Checken 10 131 19.1 6 (60) 17 33
2 AZ Lumen 20 296 21.8 3 (15) 15 33
TC Njaien 11 242 19.7 9 (82) 19 38
3 AZ Sinchu Pallen 12 273 22.2 6 (50) 8 17
TC Sambo Sotor 19 257 21.2 3 (16) 18 39
4 AZ Balo 16 220 22.0 4 (25) 17 41
TC Keur Bamba Lowe 12 226 22.0 4 (33) 20 47
Total 106 1803 21.0 39 (37) 16 36
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ence gained in individually randomized controlled
clinical trials using azithromycin, which have consis-
tently shown the drug’s potential to resolve active
trachomatous disease (18–20). It was the high rate of
reinfection in previous azithromycin trials that called
for the evaluation of the drug in mass treatment. It is
generally accepted that sequelae are more common
after repeated reinfection, and that frequent reinfec-
tion is associated with severe inflammatory changes
(28). Bobo et al. (29) have documented in children the
relationship between infection intensity, dynamics of
infection, and disease severity. A high C. trachomatis
burden is associated with persistent infection and
severe disease, whereas a low burden is associatedwith
sporadic infection and milder (follicular) disease. The
study by Detels et al. (30) of migrants has shown that
scarring does not progress in the absence of continued
exposure to reinfection.
Microbiological data (23) demonstrate that
azithromycin and tetracycline therapy lowered the
village-wide prevalence of conjunctival infection
within one year by 78% and 66%, respectively.
Variables predicting infection status in the study
cohort at the 1-year follow-up were the infection at
baseline, age, and treatment compliance. Those
participants found infected prior to treatment were
significantly less likely to be infected at one year if
they were in the azithromycin treatment group. In
addition, resolution of infection in participants with
disease at baseline was better after azithromycin than
tetracycline treatment.
Our analysis of the clinical trial data suggests
that, over a period of 12 months, oral azithromycin
has a greater impact than topical tetracycline on the
prevalence of active disease and resolution of active
trachoma. The data are also consistent with a greater
impact of azithromycin on the occurrence of new
prevalent cases. Both compounds tested were given
under optimal conditions, i.e. azithromycin was given
in three doses at weekly intervals to maximize the
coverage, and tetracycline ointment was applied by
health workers on a daily basis over 6 weeks. The
effect of different numbers of azithromycin doses
was not evaluated.
Table 2. Sex- and age-specific prevalences of active trachoma at baseline and 6 and 12 months after
treatment with azithromycin (AZ) or tetracycline (TC), by treatment group
% prevalence at % prevalence 6 months % prevalence 12 months
baseline after treatment after treatment
AZ TC AZ TC AZ TC
Males 13.4 17.6 4.2 8.4 5.9 14.9
Females 15.7 19.6 6.3 9.1 10.1 17.7
Age group (years)
0–4 40.7 47.2 10.2 22.5 18.9 41.1
5–9 22.7 32.1 7.9 12.7 9.9 18.8
10–14 7.9 12.8 3.2 3.0 2.9 12.5
515 2.9 3.2 1.9 3.1 3.2 4.2
All 14.4 18.4 5.1 8.7 7.7 16.1
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One year after treatment, the prevalence of
active trachoma was reduced by 47% (from 14.4% to
7.7%) and by 13% (from 18.4% to 16.1%) in the
azithromycin and tetracycline groups, respectively. In
children aged 0–4 years, the prevalence of the disease
one year after tetracycline treatment was close to the
pre-treatment level, while it was only half of the pre-
treatment level in those allocated to azithromycin.
Young children are notoriously difficult to treat with
ointment, and the safe and efficacious azithromycin
regimenmay be an important advance in treatment of
childhood trachoma. In school-age children, both
treatments appeared to work equally well within the
first half of the follow-up period, but disease
prevalence rose steeply in the second half among
those allocated to tetracycline. The greater efficacy of
azithromycin may have become more evident in the
longer term, through a greater reduction in the
reservoir of infection, with systemic treatment being
more likely to have a greater impact than topical
treatment on extra-ocular infection.
Oral azithromycin may have a more marked
effect than topical tetracycline on reducing C. tracho-
matis transmission, as suggested by the higher like-
lihood for participants allocated to tetracycline to be
diagnosed as new prevalent cases during follow-up.
The efficacy of azithromycin versus tetracycline
against not being identified as a new prevalent case
was 46% at 1 year. In terms of disease resolution,
tetracycline appeared to perform as well, if not better
than azithromycin during the early follow-up period,
which might be explained by the extended treatment
period of tetracycline over 6 weeks. In the subsequent
follow-up examinations, azithromycin appeared
superior in resolving active disease, presumably
because it reduced the likelihood of reinfection.
Limitations of the study
This study has a number of limitations. First, the
number of clusters randomized was very small,
leading to a small effective sample size and wide
confidence intervals. Data analysis was conducted
without taking the paired design into account, in
order to optimize what power there was (31). A
further limitation associated with randomizing only a
small number of clusters is that the two treatment
groups may have remained unbalanced with respect
to important risk factors for the outcome. In our
analyses we controlled for age, latrine ownership and,
where appropriate, the presence of active trachoma at
baseline. We cannot exclude the possibility that other
unmeasured or uncontrolled risk factors may have
confounded our comparison of azithromycin and
tetracycline. Second, we measured the prevalence
rather than the incidence of disease. It is possible that
some individuals who were not considered to have
active trachoma at any of the cross-sectional surveys
may have experienced episodes of active disease
between the surveys. This may be particularly true for
older participants. Bailey et al. (32) reported that in
the Gambia adults tended to experience short bursts
of the intense form of trachoma, while children
Table 3. Comparison of the impact of azithromycin versus topical
tetracycline on the prevalence of active trachoma, on newly
prevalent cases, and on the resolution of prevalent cases at baseline
Azithromycin Tetracycline Odds ratioa
group group
Prevalence
At 2 months 34/740 (4.6)b 34/672 (5.1) 1.09c; 0.53, 2.0 d
At 6 months 24/470 (5.1) 33/380 (8.7) 0.62c; 0.28, 1.62
At 12 months 44/571 (7.7) 68/422 (16) 0.52c; 0.34, 0.80
New prevalent cases
At 12 months 18/488 (3.7) 19/316 (6.0) 0.54e; 0.22, 1.15
At any time 22/597 (3.7) 27/597 (4.5) 0.74e; 0.39, 1.28
Resolutionf
At 2 months 86/115 (75) 98/127 (73) 0.84f; 0.51, 1.42
At 6 months 56/77 (73) 54/80 (67) 1.30f; 0.59, 2.89
At 12 months 55/81 (68) 56/105 (53) 2.02f; 1.42, 3.50
a Odds ratios estimated by logistic regression.
b Figures in parentheses are percentages.
c Estimated odds ratios adjusted for age, latrine ownership, and active trachoma status
at baseline.
d Figures in italics are 95% CI obtained by bootstrapping, using the percentile method and
taking account of the cluster randomization.
e Estimated odds ratios adjusted for age and latrine ownership. Excludes individuals with active
trachoma at baseline.
f Estimated odds ratios adjusted for age and latrine ownership. Includes only individuals
with active trachoma at baseline.
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tended to suffer prolonged episodes of TF. Never-
theless, we believe that this trial indicates the higher
and more sustained potential of azithromycin
compared with tetracycline to reduce the burden of
trachoma at community level in settings where the
condition is highly prevalent. Third, although
compliance with treatment was very high, there were
substantial losses to follow-up during the trial.
Follow-up was slightly better in the azithromycin
than in the tetracycline group. Follow-up was also
better in the younger age groups at highest risk of
active disease and in those with active disease at
baseline. These phenomena combinedmight bias the
comparison in favour of azithromycin. However,
even if we assume that all individuals who were not
seen at 12 months did not have active trachoma, the
prevalence of active disease would be lower in the
azithromycin group (4.6%) than in the tetracycline
group (7.9%). It seems unlikely, therefore, that losses
to follow-up are responsible for the differences
observed between the two groups.
Antibiotics and trachoma control
There is a consensus that antibiotics are a cornerstone
in trachoma control, and that oral treatments are more
desirable than topical formulations. Oral treatment
usually requires less frequent administration, resulting
in improved compliance and greater efficiency of
control programmes, and thus in cost-savings thatmay
well compensate for the higher drug costs. Further-
more, oral treatment may accelerate the elimination of
the infection, because such treatment is more likely to
clear C. trachomatis in extraocular reservoirs than if
treatment is confined to the conjunctiva.However, the
applicability of systemic drugs can be hampered by
adverse effects, which are of greatest concern when
mass treatment is used. Azithromycin has a better
safety profile than the oral drugs used previously (18,
33, 34), but its safety for pregnant and lactatingwomen
is not currently known.
There is reason for concern that azithromycin-
resistant pathogens may emerge if the drug is used
on a large scale, underlining the importance of both
its well-targeted use (35), and of monitoring the
development of resistance in areas where azithro-
mycin is routinely used (currently among Aborigine
children in Australia). Rapid assessment procedures
for trachoma and mapping by Geographic Informa-
tion Systems are now being introduced in order to
facilitate rational targeting of antibiotic treatment
(33). Lietman et al. (36) recently presented a
trachoma transmission model and its implications
for targeting of treatment, mass treatment intervals,
and resulting shifts in disease patterns and immunity.
The results predict that in areas where the prevalence
of trachoma in children is below 35%, annual or
biennial mass treatment (i.e. every one or two years)
would be sufficient eventually to eliminate the
disease, but that prevalences above 35% would
require biannual mass treatment (i.e. every 6 months)
— assuming universal coverage, no immigration of
infected individuals, and absence of clustering of
infection within households (37). Selective mass
treatment of children up to 10 years of age would
generally shorten the recommended treatment
intervals.
Conclusions
In the present trial with highly controlled treatment
conditions, the overall prevalence of active trachoma
was reduced by 47% in the villages that had received
azithromycin treatment 12 months before. This is a
promising start in the control of trachoma in these
communities. The marked reduction in intense
disease, which is thought to be an indicator for
future blindness, especially among the azithromycin
group, may indicate that annual mass treatment can
indeed prevent trachoma-attributable blindness.
Application of the trachoma transmission model to
aid in the design of cost-effective control pro-
grammes might prove valuable. The SAFE strategy
foresees the use of antibiotics and surgery as short-
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term interventions delivered through the health
service, and health promotion and environmental
improvements as the consolidating long-term inter-
ventions. Improvements in primary health care
services and sanitation will undoubtedly be followed
by a decline in trachoma (38). However, it is hoped
that community-based antibiotic treatment will
make the global elimination of trachoma by 2020
an achievable target even in very poor areas where
development progress is slow. The recent an-
nouncement of an azithromycin donation pro-
gramme for selected trachoma endemic countries
could lead to a major advance in the control of
blinding trachoma. n
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Re´sume´
Efficacite´ compare´e de l’azithromycine par voie orale et de la te´tracycline en application
locale dans le traitement de masse du trachome ende´mique
Objectif Comparer l’impact d’un traitement de masse
par l’azithromycine orale et la te´tracycline en application
locale sur la pre´valence du trachome actif.
Me´thodes Dans huit villages de Gambie, 1803 habi-
tants appartenant a` 106 me´nages ont e´te´ re´partis par
tirage au sort dans deux groupes de traitement, l’un
consistant en trois doses orales d’azithromycine a` une
semaine d’intervalle et l’autre en une application
quotidienne de pommade a` la te´tracycline pendant
six semaines. Des examens ophtalmologiques ont e´te´
re´alise´s avant le traitement et 2, 6 et 12 mois apre`s
celui-ci.
Re´sultats Avant le traitement, 16 % des participants
pre´sentaient un trachome actif. Deux mois apre`s le
traitement, la pre´valence du trachome e´tait de 4,6 %
dans le groupe traite´ par l’azithromycine et de 5,1 %
dans le groupe traite´ par la te´tracycline (odds ratio ajuste´
(OR) = 1,09 ; intervalle de confiance (IC) a` 95 % : 0,53-
2,02). Elle remontait ensuite a` 16 % dans le groupe
te´tracycline mais restait a` 7,7 % dans le groupe
azithromycine (OR ajuste´ a` 12 mois = 0,52 ; IC 95 % :
0,34-0,80). Au bout de 12 mois, on observait moins de
nouveaux cas dans le groupe azithromycine et le taux de
re´solution du trachome y e´tait significativement plus
e´leve´ (OR ajuste´ = 2,02 ; IC 95 % : 1,42-3,50).
Conclusion L’azithromycine par voie orale semble donc
pouvoir offrir un moyen de lutte contre le trachome
ce´citant. Elle est facile a` administrer et devrait permettre
d’obtenir une meilleure couverture que ce qui a pu eˆtre
re´alise´ jusqu’a` maintenant.
Resumen
Eficacia de la azitromicina oral frente a la tetraciclina to´pica en el tratamiento masivo
del tracoma ende´mico
Objetivo Comparar los efectos del tratamiento masivo
con azitromicina oral y con tetraciclina to´pica en la
prevalencia del tracoma activo.
Me´todos Un total de 1803 habitantes de 106 hogares
de ocho aldeas de Gambia fueron distribuidos al azar por
pares para que recibieran ya fuera tres dosis de
azitromicina a intervalos semanales o tetraciclina to´pica
diaria a lo largo de seis semanas. Se realizaron exa´menes
oftalmolo´gicos antes del tratamiento y a los 2, 6 y
12 meses del tratamiento.
Resultados Antes del tratamiento, el 16% de los
participantes en el estudio presentaban tracoma activo.
Dos meses despue´s del tratamiento la prevalencia de
tracoma era del 4,6% y del 5,1% en los grupos
tratados con azitromicina y tetraciclina, respectiva-
mente (razo´n de posibilidades (OR) ajustada = 1,09;
intervalo de confianza (IC) del 95% = 0,53, 2,02).
Posteriormente la prevalencia aumento´ al 16% en el
grupo tratado con tetraciclina, mientras que permane-
cio´ en el 7,7% en el grupo tratado con azitromicina (OR
ajustada a los 12 meses = 0,52; IC95% = 0,34, 0,80).
A los 12 meses de acabado el tratamiento, la
prevalencia de casos nuevos en el grupo tratado con
azitromicina fue menor, y la resolucio´n del tracoma fue
significativamente mejor en este grupo (OR ajus-
tada = 2,02; IC95% = 1,42, 3,50).
Conclusio´n La azitromicina oral constituye una
alternativa para combatir el tracoma causante de
ceguera. Es fa´cil de administrar, y se pueden conseguir
coberturas ma´s altas que las logradas hasta ahora.
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